Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2+ gastric cancer

摘要：

Dear Editor,Genetically engineered T cell therapy is a promising new strategy to combat cancer.The chimeric antigen receptor-expressing T cell (CART) approach has achieved success in clinical trials of patients with non-solid tumors ”1,2”.Some limitations nevertheless have emerged.Among them are restriction of the CARs to the cell surface and the risks associated with retroviral integration in the genome ”3,4”.A recent development is the design of bispecific T-cell engagers (BiTEs),a class of artificial bispecific antibodies that are composed of two single-chain variable fragments (scFv),one specific for a T-cell-specific molecule,usually CD3,and the other specific for a tumor-associated antigen ”5-8”.

所属期刊栏目：26

资助基金：This work was supported by the National Natural Science Foundation of China 31400772,81273215 and 81420108005,the Science and Technology Commission of Shanghai Municipality 13JC1407700 and 15JC1401200,the Joint Research Project on Major Diseases of Shanghai Health System 2014ZYJB0302,the China Postdoctoral Science Foundation 2014M551329 and 2015T80397,and the Major Program of Development Fund for Shanghai Zhangjiang National Innovation Demonstration Zone ZJ2014-ZD-002.

在线出版日期：2016-08-16（万方平台首次上网日期，不代表论文的发表时间）

页码：850-853